HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
2022 · EBioMedicine · 25 citations
https://doi.org/10.1016/j.ebiom.2022.104205
H
Holly Tovey
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
141
Papers
2.3K
Citations
14
h-index
20
i10-index
Holly Tovey is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics. The author has an h-index of 14, co-authored 120 publications.
ORCID: 0000-0002-8324-0055Papers by this author
worksA simple digital image analysis system for automated Ki67 assessment in primary breast cancer
2021 · Histopathology · 21 citations
https://doi.org/10.1111/his.14355
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
2023 · Nature Communications · 21 citations
https://doi.org/10.1038/s41467-023-39613-z
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
2020 · Annals of Oncology · 20 citations
https://doi.org/10.1016/j.annonc.2020.10.475
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)
2023 · Breast Cancer Research · 14 citations
https://doi.org/10.1186/s13058-023-01626-3
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
2022 · Breast Cancer Research · 7 citations
https://doi.org/10.1186/s13058-022-01556-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat